Literature DB >> 29124434

Effect of prednisone treatment for 30 and 90 days on bone metabolism in collagen-induced arthritis (CIA) rats.

Xinle Zhang1, Xuna Wu1, Yalin Min1, Jiaqi Lu1,2, Xuemei Zhang1, Wenshuang Chen1, Liyi Zou1, Xiaohua Lv1, Liao Cui1, Bilian Xu3.   

Abstract

Glucocorticoids (GCs) are often prescribed to treat rheumatoid arthritis (RA) in the long term, but there is still controversy in the administration of GCs, mainly because of the adverse reactions such as osteoporosis. Numerous studies have demonstrated that osteoporosis could be induced by GCs in normal rats. However, few experiments have focused on whether osteoporosis could be induced or aggravated by GCs in collagen induced arthritis (CIA) rats. We have investigated bone changes in CIA rats treated with prednisone at 4.5 mg/kg/day for 30 and 90 days by bone histomorphometry, bone mineral density (BMD), micro-CT, biomechanical test, and enzyme-linked immunosorbant assay. We found that high bone turnover osteoporosis was shown in CIA rats. Prednisone treatment for 30 and 90 days improved articular structure and decelerated the degeneration of the femur in CIA rats, but did not improve BMD and bone biomechanics. We conclude that osteoporosis was not aggravated in CIA rats treated with prednisone for 30 and 90 days. On the contrary, prednisone treatment for 30 and 90 days could prevent bone loss of the femur in CIA rats. There was a negative effect on bone metabolism in CIA rats treated with prednisone for 90 days.

Entities:  

Keywords:  Collagen-induced arthritis; Osteroporosis; Prednisone; Rats; Rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 29124434     DOI: 10.1007/s00774-017-0880-1

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  31 in total

1.  Quantitation of glucocorticoid receptor alpha and NF-κB pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients.

Authors:  L O Cavalcante; M R Melo; V G Dinis; R B Castro; B D B Souza; C A Longui
Journal:  Genet Mol Res       Date:  2010-11-23

2.  Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction.

Authors:  Debby den Uyl; Daniel H van Raalte; Michael T Nurmohamed; Willem F Lems; Johannes W J Bijlsma; Jos N Hoes; Ben A C Dijkmans; Michaela Diamant
Journal:  Arthritis Rheum       Date:  2012-03

Review 3.  Glucocorticoid receptor beta in acute and chronic inflammatory conditions: clinical implications.

Authors:  Annelise Goecke; Julia Guerrero
Journal:  Immunobiology       Date:  2005-12-27       Impact factor: 3.144

4.  Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Amalia A van Everdingen; Johannes W G Jacobs; Dirk R Siewertsz Van Reesema; Johannes W J Bijlsma
Journal:  Ann Intern Med       Date:  2002-01-01       Impact factor: 25.391

Review 5.  Prevention and treatment of bone changes associated with exposure to glucocorticoids.

Authors:  Amy H Warriner; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 6.  Clinical features associated with glucocorticoid receptor polymorphisms. An overview.

Authors:  Laura Manenschijn; Erica L T van den Akker; Steven W J Lamberts; Elisabeth F C van Rossum
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

7.  Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis.

Authors:  Justin C Earp; Debra C Dubois; Diana S Molano; Nancy A Pyszczynski; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2008-04-30       Impact factor: 4.030

8.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

Authors:  Erik Lubberts; Marije I Koenders; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Christina J J Coenen-de Roo; Leo A B Joosten; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2004-02

Review 9.  Involvement of the glucocorticoid receptor in the pathogenesis of rheumatoid arthritis.

Authors:  Gunther Neeck; Andreas Kluter; Helmut Dotzlaw; Martin Eggert
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

Review 10.  RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases.

Authors:  Hisataka Yasuda
Journal:  World J Orthop       Date:  2013-10-18
View more
  4 in total

1.  Transcriptomics-based analysis of the mechanism by which Wang-Bi capsule alleviates joint destruction in rats with collagen-induced arthritis.

Authors:  Haiyang Shu; Hanxiao Zhao; Yingjie Shi; Cheng Lu; Li Li; Ning Zhao; Aiping Lu; Xiaojuan He
Journal:  Chin Med       Date:  2021-04-12       Impact factor: 5.455

2.  Enhancing Prednisone-Based Arthritis Therapy with Targeted IL-27 Gene Delivery.

Authors:  Adriana A Marin; Richard E Decker; Shreya Kumar; Zachary Lamantia; Hiroki Yokota; Todd Emrick; Marxa L Figueiredo
Journal:  Bioengineering (Basel)       Date:  2022-06-09

3.  Developing cerium modified gold nanoclusters for the treatment of advanced-stage rheumatoid arthritis.

Authors:  Sen Lin; Wei Gao; Jiachen Sun; Kai Gao; Dan Li; Xifan Mei
Journal:  Mater Today Bio       Date:  2022-06-23

Review 4.  Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis.

Authors:  Peter Pietschmann; Maria Butylina; Katharina Kerschan-Schindl; Wolfgang Sipos
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.